Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 4 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Jan. 16, 2023 PROK A 1,011,500 · · 1,011,500 Direct · Acquired (price as of 2026-10-02)
Oct. 20, 2022 PROK A 3,639,607 · · 3,639,607 Direct · Acquired (price as of 2026-10-02)
July 11, 2022 PROK A 4,944,938 · · 4,944,938 Direct · Acquired (price as of 2026-10-02)
July 11, 2022 PROK A 4,944,938 · · 4,944,938 Direct · Acquired (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Jan. 16, 2023 PROK Employee stock option (right to buy) Class A Ordinary Shares (1,011,500) $8.43 Jan. 16, 2033 1,011,500 Acquired
Oct. 20, 2022 PROK Employee stock option (right to buy) Class A Ordinary Shares (3,639,607) $10.33 Oct. 20, 2032 3,639,607 Acquired
July 11, 2022 PROK Common Units in ProKidney LP [F3] Class A Ordinary Shares (4,944,938) · · 4,944,938 Acquired
July 11, 2022 PROK Class B Ordinary Shares Class A Ordinary Shares (4,944,938) · · 4,944,938 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

PROK

CEO
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2023 $544,107 · · $6,115,934 $194,343 · $720,793 $7,575,176
2022 $600,000 · $16,964,293 $28,198,867 $344,270 · $26,135 $46,133,566

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.